Risk factors for de novo hepatitis B during solid cancer treatment

作     者：Rie Sugimoto Masayuki Furukawa Takeshi Senju Yoshihusa Aratake Yuki Tanaka Hiroki Inada Tatsuya Noguchi Lingaku Lee Masami Miki Yuji Maruyama Risa Hashimoto Terumasa Hisano Mototsugu Shimokawa 

作者机构：Department of Hepato-Biliary-PancreatologyNational Hospital Organization Kyushu Cancer CenterFukuoka City 811-1395Fukuoka PrefectureJapan National Hospital Organization Kyushu Cancer CenterClinical Research InstituteFukuoka City 811-1395Fukuoka PrefectureJapan Department of BiostatisticsYamaguchi University Graduate School of MedicineUbe City 755-8505Yamaguchi PrefectureJapan 

出 版 物：《World Journal of Clinical Cases》 (世界临床病例杂志)

年 卷 期：2020年第8卷第24期

页      面：6264-6273页

核心收录：

学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 1002[医学-临床医学] 100214[医学-肿瘤学] 100401[医学-流行病与卫生统计学] 10[医学] 

基　　金：Supported by Eisai Corporation No.HHCS20181030011 

主　　题：Hepatitis B Reactivation Solid cancer treatment Digestion and absorption organ Hepatitis B surface antibody Hepatitis B core antibody titer 

摘      要：BACKGROUND Reactivation of hepatitis B virus(HBV)during anticancer treatment is a critical *** treating patients with solid tumors,it is unclear whether specific cancer types or treatments affect HBV reactivation in hepatitis B surface antigen(HBsAg)-negative and hepatitis B core antibody(HBcAb)-positive patients,socalled de novo hepatitis B *** risk of de novo hepatitis B may vary based on different background *** To determine the frequency and risk factors for de novo hepatitis B during solid tumor *** This retrospective cohort study comprised 1040 patients without HBsAgs and with HBcAbs and/or hepatitis B surface antibodies(HBsAbs).The patients were treated for solid cancer from 2008 to 2018 at the National Kyushu Cancer Center and underwent HBV DNA *** characteristics and disease and treatment information were *** DNA measurements were performed using TaqMan polymerase chain reaction(PCR).To identify the risk factors associated with HBV DNA expression,the age,sex,original disease,pathology,treatment method,presence or absence of hepatitis C virus(HCV),and HBsAb and/or HBcAb titers of all subjects were *** patients with HBV DNA,the time of appearance,presence of HBsAgs and HBsAbs at the time of appearance,and course of the subsequent fluctuations in virus levels were also *** Among the 1040 patients,938 were HBcAb positive,and 102 were HBcAb negative and HBsAb *** DNA expression was observed before the onset of treatment in nine patients(0.9%)and after treatment in 35 patients(3.7%),all of whom were HBcAb *** HBV reactivation group showed significantly higher median HBcAb values[9.00(8.12-9.89)vs 7.22(7.02-7.43),P=0.0001]and significantly lower HBsAb values(14 vs 46,P=0.0342)than the group without ***,the reactivated group showed a significantly higher proportion of cancers in organs related to digestion and absorption(79.0%vs 58.7%,